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ORIGINAL RESEARCH • GASTROINTESTINAL IMAGING
Hepatocellular carcinoma (HCC) is the fifth most com-mon cancer in the world and ranked second for deaths 
caused by cancer (1,2). Noninvasive imaging plays an im-
portant role in the diagnosis of HCC, which is essential for 
appropriate patient treatment (3,4). Imaging of small HCC 
is challenging because of the complexity of dual blood sup-
ply to the liver, multistage hepatic carcinogenesis, overlap-
ping of microvascular perfusion of regenerative and dysplas-
tic nodules, and different histologic grades for HCC. Over 
the years, real-time low mechanical index contrast agent–en-
hanced US has been used in Europe and Asia as a first-line 
diagnostic modality for HCC and is recommended by sev-
eral national and international professional societies (3,5–9). 
Despite reported high sensitivity and positive predictive val-
ue of contrast-enhanced US for the diagnosis of HCC in cir-
rhosis, the diagnosis of small HCC, especially those smaller 
than 2 cm, remains a challenge despite advances in US and 
harmonic imaging techniques (3,10–12). Only recently was 
contrast-enhanced US for liver indication approved in the 
United States (13). To improve the diagnostic accuracy of 
HCC and facilitate communication among radiologists and 
between radiologists and physicians, the American College 
of Radiology developed the contrast-enhanced US Liver Im-
aging Reporting and Data System (CEUS LI-RADS) as a 
standardized reporting system for liver nodules in patients 
at risk for HCC (14,15). However, the diagnostic accuracy 
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Background: American College of Radiology contrast agent–enhanced US Liver Imaging Reporting and Data System (CEUS LI-
RADS) was developed to improve the accuracy of hepatocellular carcinoma (HCC) diagnosis at contrast agent2enhanced US. 
However, to the knowledge of the authors, the diagnostic accuracy of the system in characterization of liver nodules 20 mm or 
smaller has not been fully evaluated.
Purpose: To evaluate the diagnostic accuracy of CEUS LI-RADS in diagnosing HCC in liver nodules 20 mm or smaller in patients 
at risk for HCC.
Materials and Methods: Between January 2015 and February 2018, consecutive patients at risk for HCC presenting with untreated 
liver nodules 20 mm or less were enrolled in this retrospective double-reader study. Each nodule was categorized according to the 
CEUS LI-RADS and World Federation for Ultrasound in Medicine and Biology (WFUMB)–European Federation of Societies for 
Ultrasound in Medicine and Biology (EFSUMB) criteria. Diagnostic performance of CEUS LI-RADS and WFUMB-EFSUMB 
characterization was evaluated by using tissue histologic analysis, multiphase contrast-enhanced CT and MRI, and imaging follow-
up as reference standard and compared by using McNemar test.
Results: The study included 175 nodules (mean diameter, 16.1 mm 6 3.4) in 172 patients (mean age, 51.8 years 6 10.6; 136 
men). The sensitivity of CEUS LR-5 versus WFUMB-EFSUMB criteria in diagnosing HCC was 73.3% (95% confidence inter-
val [CI]: 63.8%, 81.5%) versus 88.6% (95% CI: 80.9%, 94%), respectively (P , .001). The specificity of CEUS LR-5 versus 
WFUMB-EFSUMB criteria was 97.1% (95% CI: 90.1%, 99.7%) versus 87.1% (95% CI: 77%, 94%), respectively (P = .02). No 
malignant lesions were found in CEUS LR-1 and LR-2 categories. Only two nodules (of 41; 5%, both HCC) were malignant in 
CEUS LR-3 category. The incidences of HCC in CEUS LR-4, LR-5, and LR-M were 48% (11 of 23), 98% (77 of 79), and 75% 
(15 of 20), respectively. Two of 175 (1.1%) histologic analysis2confirmed intrahepatic cholangiocarcinomas were categorized as 
CEUS LR-M by CEUS LI-RADS and misdiagnosed as HCC by WFUMB-EFSUMB criteria.
Conclusion: The contrast-enhanced US Liver Imaging Reporting and Data System (CEUS LI-RADS) algorithm was an effective 
tool for characterization of small (20 mm) liver nodules in patients at risk for hepatocellular carcinoma (HCC). Compared with 
World Federation for Ultrasound in Medicine and Biology2European Federation of Societies for Ultrasound in Medicine and 
Biology criteria, CEUS LR-5 demonstrated higher specificity for diagnosing small HCCs with lower sensitivity.
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Patient Selection
Between January 2015 and February 2018, consecutive he-
patic contrast-enhanced US examinations performed in a West 
China tertiary academic medical center hospital were retro-
spectively evaluated. Patients with risk factors for HCC who 
presented with untreated liver nodules with maximal diameter 
of 20 mm or smaller at initial imaging (screening or diagnostic 
US, or contrast-enhanced CT or MRI performed as a part of 
standard clinical care) were included. All nodules were visible 
at baseline US. Risk factors for HCC were defined in accor-
dance to American Association for the Study of Liver Diseases 
guidelines, which include cirrhosis of any cause and/or chronic 
hepatitis B (3).
Clinical indications for contrast-enhanced US were as fol-
lows: a US screening examination positive for liver nodule 
in patients at risk for HCC per current clinical standards 
of practice, the WFUMB-EFSUMB and CEUS LI-RADS 
guidelines; focal liver observation at single-phase CT or 
unenhanced MRI performed for other clinical reasons; in-
determinate focal liver observation at multiphase contrast-
enhanced CT or MRI; and definite HCC on CT or MRI 
images in preparation for or during tissue sampling, surgical 
resection, or percutaneous ablation treatment. Patients with 
definitely benign findings at contrast-enhanced US returned 
to standard surveillance. Patients with findings that were 
indeterminate or suspicious for HCC at contrast-enhanced 
US or multiphase CT or MRI were referred to a multidis-
ciplinary discussion and further management (ie, follow-up 
imaging, tissue sampling, or treatment).
US Examination
Conventional precontrast gray-scale and contrast-enhanced 
US examinations were performed by using a US system 
(IU22; Philips Medical Solutions, Mountain View, Calif ) 
with a C521 MHz convex or L923 MHz linear probe. Pulse 
inversion harmonic imaging and mechanical index of less 
than 0.1 were used for contrast-enhanced US examinations 
with technical recommendations by following the WFUMB-
EFSUMB and CEUS LI-RADS guidelines (5,16). The im-
age focus was placed below the region of interest and a dual 
screen format was used for all the contrast-enhanced US 
examinations showing a gray-scale image alongside the con-
trast-specific image. A bolus injection of 1.2–2.4 mL sulfur 
hexafluoride2filled microbubble contrast agent (SonoVue; 
Bracco, Milan, Italy) was administered via a 20-gauge cath-
eter line placed in the antecubital vein. A 5-mL flush of 0.9% 
sodium chloride solution was followed after the injection of 
the contrast agent (SonoVue; Bracco). The imaging timer was 
started simultaneously with the completion of the contrast 
agent injection (SonoVue; Bracco). The region of interest, in-
cluding target lesion and surrounding liver parenchyma, was 
imaged continuously for the first 60 seconds and intermit-
tently afterward until washout was confidently observed or 
liver parenchymal enhancement faded, typically 5 minutes or 
longer (17). The set of contrast-enhanced US imaging was 
stored on the hard drive of the US system and copied to por-
table hard drive for later evaluation.
Abbreviations
CEUS LI-RADS = contrast agent2enhanced US Liver Imaging Report-
ing and Data System, CI = confidence interval, EFSUMB = European 
Federation of Societies for Ultrasound in Medicine and Biology, HCC = 
hepatocellular carcinoma, WFUMB = World Federation for Ultrasound 
in Medicine and Biology
Summary
The American College of Radiology contrast agent–enhanced US 
Liver Imaging Reporting and Data System effectively categorized 
liver nodules 20 mm or smaller in patients at risk for hepatocellular 
carcinoma. Nodules categorized as CEUS LR-5 demonstrated high 
specificity, positive predictive value, and positive likelihood ratio in 
diagnosing small hepatocellular carcinoma.
Key Results
 n By using the American College of Radiology contrast agent–en-
hanced US Liver Imaging Reporting and Data System (CEUS 
LI-RADS), nodules categorized as CEUS LR-5 demonstrated 
sensitivity and specificity of 73% and 97%, respectively, for the 
diagnosis of hepatocellular carcinoma (HCC) 20 mm or less in 
patients at risk for HCC.
 n By using World Federation for Ultrasound in Medicine and 
Biology (WFUMB)2European Federation of Societies for 
Ultrasound in Medicine and Biology (EFSUMB) criteria for the 
same patients, the sensitivity and specificity were 89% and 87%, 
respectively (P , .001 for comparison with CEUS LI-RADS).
 n No malignancy was found in nodules categorized as CEUS LR-1 
and LR-2. Five percent of CEUS LR-3 nodules were malignant; 
the incidences of HCC in CEUS LR-4, LR-5, and LR-M catego-
ries were 48%, 97%, and 75%, respectively.
 n Two of 175 (1.1%) nodules diagnosed at pathologic analysis as in-
trahepatic cholangiocarcinomas were categorized as CEUS LR-M 
by CEUS LI-RADS and misdiagnosed as HCC by WFUMB-
EFSUMB criteria.
of CEUS LI-RADS in its characterization of small liver nodules 
(20 mm), to our knowledge, has not been fully evaluated.
Until recently, World Federation for Ultrasound in Medicine 
and Biology (WFUMB)2European Federation of Societies for 
Ultrasound in Medicine and Biology (EFSUMB) 2012 guidelines 
were widely accepted as the criteria for diagnosis of HCC. They 
were intended to create a standard protocol for the use of contrast 
agent at US in liver application on an international basis and im-
prove the treatment of patients worldwide. The key contrast-en-
hanced US features for the diagnosis of HCC in liver cirrhosis by 
WFUMB-EFSUMB criteria are arterial phase hyperenhancement 
followed by washout in the late phase (5).
CEUS LI-RADS was initially introduced in 2016 and has 
different diagnostic features and characterization algorithm com-
pared with WFUMB-EFSUMB criteria. The size of a lesion, the 
type and degree of arterial phase enhancement, the presence of 
washout, and the timing and degree of washout are the major fea-
tures used for categorization (16).
The aim of our study was to evaluate the diagnostic accuracy 
of the American College of Radiology CEUS LI-RADS and 
WFUMB-EFSUMB criteria for diagnosing HCCs in liver nod-
ules 20 mm or smaller in patients at risk for HCC.
Materials and Methods
Our retrospective study was approved by the institutional eth-
ics committee and written informed consent was waived.
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Table 1: Rating Criteria of WFUMB-EFSUMB and CEUS LI-RADS
Rating Criteria with Nodule Size Arterial Phase Portal or Late Phase
WFUMB-EFSUMB
 Nodule size not required Hyperenhancement Washout
CEUS LI-RADS
 LR-5
  1 cm Not rim, not peripheral discontinuous globular hyperenhancement Late mild washout
 LR-M
  Nodule size not required Rim hyperenhancement Washout
  Nodule size not required Not rim, not peripheral discontinuous globular hyperenhancement Early washout (,60 sec) or  
marked out at 120 
seconds
 LR-4
  2 cm No hyperenhancement Late and mild washout
  1 cm Not rim, not peripheral discontinuous globular hyperenhancement No washout
  ,1 cm Not rim, not peripheral discontinuous globular hyperenhancement Late and mild washout
 LR-3
  ,2 cm No hyperenhancement No washout or late and 
mild washout
  2 cm No hyperenhancement No washout
  ,1 cm Not rim, not peripheral discontinuous globular hyperenhancement No washout
 LR-2
  ,1 cm Isoenhancement No washout
 LR-1
  Nodule size not required Definitely benign arterial phase pattern (cyst, hemangioma, focal fatty 
deposition/sparing or other definitely benign observation)
No washout
Note.—CEUS LI-RADS = contrast-enhanced US Liver Imaging Reporting and Data System, EFSUMB = European Federation of Societies 
for Ultrasound in Medicine and Biology, WFUMB = World Federation for Ultrasound in Medicine and Biology.
Reference Standard
A composite reference standard was used. All observations 
with LR-1 classification at contrast-enhanced CT or MRI 
were considered benign. All lesions with LR-5 classification at 
contrast-enhanced CT or MRI were considered to be HCC. 
In patients with lesions classified as CEUS LR-1, contrast-
enhanced CT or MRI was used as reference standard. In pa-
tients with lesions classified as CEUS LR-2, LR-3, and LR-
4, imaging follow-up or tissue sampling was performed per 
multidisciplinary discussion recommendations. Lesions with 
a size increase less than 50% in 12 months and without pro-
gression to a higher CEUS LI-RADS category at follow-up 
imaging were classified as benign. Observations with a size 
increase greater than 50% at follow-up imaging, additional 
contrast-enhanced CT or MRI, or tissue sampling was per-
formed per multidisciplinary discussion recommendations. 
Indeterminate findings that progressed to LR-5 at follow-up 
imaging were considered to be HCC. In patients with CEUS 
LR-M observations, histologic tissue analysis was used as ref-
erence standard. Patients with CEUS LR-3 and LR-4 obser-
vations without histologic diagnosis that remained indeter-
minate at follow-up imaging were removed from the analysis 
because of lack of a reference standard.
Tissue Sampling
Tissue sample of the lesion was obtained by surgical resec-
tion or US-guided biopsy. Biopsy was performed by using an 
Figure 1:  Study population flowchart. HCC = hepatocellular carcinoma.
18-gauge core needle with a 15- or 22-mm throw (Bard-Mag-
num Biopsy Instrument MN1816; Bard Medical, Covington, 
Ga) with real-time US guidance. The liver background of the 
surgical or biopsied specimen was evaluated at pathologic anal-
ysis and staged by using Scheuer fibrosis staging.
Contrast-enhanced US Imaging Analysis
Two certified radiologists (Q.L. and J.W.L., with more than 
10 years and 5 years of experience in liver contrast-enhanced 
US, respectively) who were blinded to reference standard 
Accuracy of CEUS LI-RADS in Small Liver Nodules for Diagnosis of HCC
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ture; and tumor in vein, size change at follow-up imaging (16). 
For characterization of the lesion on the basis of WFUMB-EF-
SUMB criteria, presence of arterial phase hyperenhancement 
and washout were documented (5). To better understand why 
small HCC nodules could manifest with different enhancing 
patterns, correlation between histologic HCC tumor grading 
and CEUS LI-RADS classification was performed.
Treatment Options
All patients with focal liver observations requiring treatment 
were reviewed at the multidisciplinary discussion. After that, 
all treatment options including liver resection, radiofrequency 
ablation, and embolization were discussed with the patients in 
detail. The final decision on treatment approach was on the 
basis of the patient preference.
Statistical Analysis
Qualitative data are presented as numbers and percentage. 
Quantitative data are presented as mean 6 standard deviation. 
Comparison of the rate of poorly differentiated HCCs in LR-5 
and LR-M was performed by using the x2 test. Characteristics 
of each liver nodule at contrast-enhanced US were registered 
separately and were processed blindly for statistical evaluation. 
The unit of analysis was each liver nodule rather than each pa-
tient. For category CEUS LR-5 and WFUMB-EFSUMB char-
acterization, the sensitivity, specificity, positive predictive value, 
negative predictive value, positive likelihood ratio, and negative 
likelihood ratio for HCC were calculated by using standard 
procedures (18). Estimated values of sensitivity, specificity, and 
accuracy of LR-5 and WFUMB-EFSUMB criteria in diagnos-
ing HCC were compared by using the McNemar test. Weighted 
k value was calculated to measure interobserver agreement of 
CEUS LI-RADS classifications of the nodules. The strength of 
agreement was interpreted according to the classification for k as 
follows: 020.20, poor agreement; 0.2120.40, fair agreement; 
0.4120.60, moderate agreement; 0.6120.80, substantial agree-
ment; and 0.8121.00, almost perfect agreement. Significance 
was indicated by a P value less than .05. Statistical analyses were 
performed by using commercially available statistical software 
(MedCalc10.4.7.0; MedCalc Software, Ostend, Belgium).
Results
Patients and Liver Nodule Characteristics
On the basis of the selection criteria, a total of 175 nodules 
in 172 patients were included (Fig 1). Three patients had two 
nodules each. The mean size of liver nodules was 16.1 mm 6 
3.4. Clinical characteristics of patients including age, sex, cause 
of liver disease, nodule size, fibrosis stage, and tumor histo-
pathologic results are in Table 2.
Of the 172 patients (mean age, 51.8 years 6 10.6), 136 
(79.1%) were men. Histopathologic tissue analysis of 124 of 
175 nodules (70.9%) was obtained, including 114 surgical spec-
imens and 10 US-guided core biopsies. The fibrosis staging and 
etiologic causes are listed in Table 2.
Overall, the numbers of nodules proved by reference standard 
were 124 by pathologic analysis, 12 by initial contrast-enhanced 
results and other imaging test results reviewed the contrast-
enhanced US examinations in the liver nodules independently 
and assigned a category according to CEUS LI-RADS (2017 
version) and WFUMB-EFSUMB criteria (Table 1). If no con-
sensus was reached, arbitration from a blinded expert radiolo-
gist (A.L., with 20 years of experience) was performed. The 
following diagnostic features were used to characterize each 
nodule on the basis of CEUS LI-RADS: nodule size; arte-
rial phase enhancement and its pattern; presence, timing, and 
degree of washout; mosaic and nodule-in-nodule architec-
Table 2: Clinical and Pathologic Information
Characteristic Result
Mean age (y)* 51.8 6 10.6 (21–78)
Sex
 Men 136 (79)
 Women 36 (21)
Mean nodule size (mm)* 16.1 6 3.4 (8–20)
Liver disease etiologic cause
 HBV 158 (91.9)
 HCV 6 (3.5)
 HBV and HCV 1 (0.6)
 PBC 1 (0.6)
 Alcohol 1 (0.6)
 Unknown etiology 5 (2.9)
Fibrosis stage
 S1 2 (1.2)
 S2 10 (5.8)
 S3 17 (9.9)
 S4 84 (48.8)
 NA 59 (34.3)
Pathologic Analysis
 HCC 104 (59.4)
  Well differentiated 1
  Moderately differentiated 78
  Poorly differentiated 25
 DN/RN 11 (6.3)
 FNH 1 (0.6)
 Hemangioma 3 (1.7)
 Intrahepatic cholangiocarcinoma 2 (1.1)
 Reactive lymphoid hyperplasia 1 (0.6)
 Biliary adenoma 1 (0.6)
 NEN 1 (0.6)
 No pathologic analysis
Contrast-enhanced CT or MRI
 Hemangioma 12 (6.9)
Follow-up 39 (22.3)
 ,50% size increase in 12 months 38 (21.7)
 50% size increase in 12 months 1 (0.6)
Note.—Unless otherwise indicated, data are liver nodules (n = 
175) or patients (n =172) and data in parentheses are percentag-
es. Mean data are 6 standard deviation. DN = dysplastic nodule, 
FNH = focal nodular hyperplasia, HBV = hepatitis B virus, 
HCC = hepatocellular carcinoma, HCV = hepatitis C virus,  
RN = regenerative nodule, NA = not available, NEN =  
neuroendocrine neoplasm, PBC = primary biliary cirrhosis.
* Data in parentheses are range.
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Table 3: Nodules in CEUS LI-RADS Categories and WFUMB-EFSUMB Criteria
Category
No. of Nodules  
(n = 175)*
Incidence of  
HCC (%)
Incidence of  
Malignancy (%)
Reference Standard (No. of Nodules)
Pathologic Analysis
Contrast-enhanced  
CT or MRI Follow-up
CEUS LI-RADS
LR-1 10 (5.7) 0 0 1 9 0
 LR-2 2 (1.1) 0 0 0 0 2
 LR-3 41 (23.4) 5 (2/41) 5 (2/41) 2 3 36
 LR-4 23 (13.1) 48 (11/23) 52 (12/23) 22 0 1
 LR-5 79 (45.1) 98 (77/79) 98 (77/79) 79 0 0
 LR-M 20 (11.4) 75 (15/20) 85 (17/20) 20 0 0
WFUMB-EFSUMB  
criteria
102 (58.3) 91.2 (93/102) 93.1 (95/102) 102 0 0
Note.—Unless otherwise indicated, data in parentheses are numerators/denominators. CEUS LI-RADS = contrast-enhanced US Liver 
Imaging Reporting and Data System, EFSUMB = European Federation of Societies for Ultrasound in Medicine and Biology, HCC = hepa-
tocellular carcinoma, WFUMB = World Federation for Ultrasound in Medicine and Biology.
* Data in parentheses are percentages.
Table 4: Imaging Characteristics of Different Types of Small Liver Nodules
Image Features
Malignant Le-
sions  (n = 108) Benign Lesions (n = 67)
Total
HCC  
(n = 105)
ICC  
(n = 2)
NEN  
(n = 1)
RN/DN  
(n = 49)
Hemangioma  
(n = 15)
FNH  
(n = 1)
Biliary Adenoma  
(n = 1)
RLH  
(n = 1)
Gray-scale echogenicity
 Hyperechoic 21 … … 15 14 … … … 50
 Hypoechoic 84 2 1 34 1 1 1 1 125
Arterial phase
 Hyperenhancement 131
  Homogeneous 97 2 1 9 1 1 1 1 113
  Inhomogenous 4 … … … 2 … … … 6
  Rim 1 … … … 1 … … … 2
  Peripheral nodular … … … … 10 … … … 10
 Isoenhancement 1 … … 12 … … … … 13
 Hypoenhancement 2 … … 28 1 … … … 31
Late phase enhancements
 Isoenhancement 11 … 1 37 1 … … … 50
 Hypoenhancement 94 2 … 12 4 1 1 1 115
 Hyperenhancement … … … … 10 … … … 10
Washout
 ,60 seconds 14 2 … … 1 … … 1 18
 Marked, 120 seconds 2 1 … … 1 … … … 4
Note.—Data are numbers of nodules. DN = dysplastic nodule, FNH = focal nodular hyperplasia, HCC = hepatocellular carcinoma, ICC = 
intrahepatic cholangiocarcinoma, NEN = neuroendocrine neoplasm, RLH = reactive lymphoid hyperplasia, RN = regenerative nodule.
CT or contrast-enhanced MRI, and 39 by follow-up (Table 3). 
The time interval between contrast-enhanced US and biopsy or 
operation was 13 days 6 7.
Interobserver Agreement in CEUS LI-RADS Classification
The rating of liver nodules according to CEUS LI-RADS by 
readers with different level of experience in contrast-enhanced 
US study of the liver had excellent interobserver agreement 
with k value of 0.84.
Distribution of CEUS LI-RADS Categories
Frequencies of CEUS LI-RADS categories and incidences of 
HCC and malignancy of each category are in Table 3.
US characteristics of 175 enrolled liver nodules are listed in 
Table 4. Nondiscontinuous peripheral nodular arterial phase 
hyperenhancement was seen in 121 lesions, including 113 le-
sions with homogeneous hyperenhancement, six lesions with 
inhomogeneous hyperenhancement, and two lesions with rim 
hyperenhancement.
Accuracy of CEUS LI-RADS in Small Liver Nodules for Diagnosis of HCC
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Figure 2: Images show a nodule categorized as LR-3 in a 44-year-old woman with chronic hepatitis B. (a) A 2-cm hyperechoic nodule (caliper) was demonstrated at 
conventional gray-scale US in the right lobe of the liver. (b) Arterial phase hypoenhancement (arrow) was shown at contrast-enhanced US. (c) The lesion showed isoen-
hancement compared with the surrounding liver parenchyma in the portal and late phase. (d) The patient underwent US-guided biopsy because of markedly elevated 
a-fetoprotein (729 ng/mL) and the lesion was proved to be moderately differentiated hepatocellular carcinoma at pathologic analysis; image shows hematoxylin-eosin 
staining (magnification, 3400).
Washout was observed in 115 of 175 liver nodules 
(65.7%). Early washout with onset time less than 60 seconds 
was seen in 18 nodules, of which 14 nodules (78%) were 
proved to be HCC at histopathologic analysis. Early washout 
(,60 seconds) was observed in both intrahepatic cholangio-
carcinomas in our series. Five nodules demonstrated marked 
washout within 120 seconds including two HCCs, two in-
trahepatic cholangiocarcinomas, and one hemangioma. No 
malignant nodules were found in the CEUS LR-1 and LR-2 
categories. Only two nodules (of 41; 5%; both HCC) were 
malignant in the CEUS LR-3 category (Fig 2), and they were 
diagnosed at histopathologic analysis and at follow-up con-
trast-enhanced CT.
According to WFUMB-EFSUMB criteria, the typical con-
trast-enhanced US pattern for HCC was hyperenhancement 
in the arterial phase followed by washout in the portal-venous 
phases (5). This pattern was displayed in 102 nodules in our 
series, which included 79 LR-5, three LR-4, and 20 LR-M nod-
ules if they were categorized by CEUS LI-RADS.
Diagnostic Accuracy of CEUS LI-RADS and  
WFUMB-EFSUMB Criteria
Overall, 79 of 175 nodules (45.1%) were categorized as CEUS 
LR-5 (Fig 3). The sensitivity, specificity, positive predictive value, 
negative predictive value, positive likelihood ratio, negative like-
lihood ratio, and disease prevalence of CEUS LR-5 for diagnos-
ing HCC were 73.3% (95% confidence interval [CI]: 63.8%, 
81.5%), 97.1% (95% CI: 90.1%, 99.7%), 97.5% (95% CI: 
90.7%, 99.3%), 70.8% (95% CI: 63.8%, 77%), 25.7 (95% 
CI: 6.5, 101.1), 0.3 (95% CI: 0.2, 0.4), and 60%, respectively 
(Table 5). Two high-grade dysplastic nodules were categorized 
as LR-5.
Twenty-three nodules (of 175; 13.1%) were categorized 
as CEUS LR-4, which corresponded to 11 HCCs (48%), 
nine regenerative or dysplastic nodules (39%) (Fig 4), one fo-
cal nodular hyperplasia, one neuroendocrine tumor, and one 
hemangioma.
Twenty nodules (of 175; 11.4%) were categorized as CEUS 
LR-M, which corresponded to 15 HCCs (75%) (Fig 5), two 
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Figure 3: LR-5 nodule in a 45-year-old man with chronic hepatitis B. (a) A 1.3-cm hypoechoic nodule (arrow) in the left lateral segment of the liver was shown at con-
ventional gray-scale US. (b) Homogeneous hyperenhancement (arrow) in the arterial phase was shown at contrast-enhanced US. (c) The lesion was seen at isoenhance-
ment at 60 seconds after contrast agent (SonoVue; Bracco) injection. (d) Mild washout (arrow) in the late phase was shown. The lesion was classified as LR-5 according to 
the findings of contrast-enhanced US. Moderately differentiated hepatocellular carcinoma and cirrhosis (S4) was confirmed at histopathologic analysis.
intrahepatic cholangiocarcinomas (Fig 6), one reactive lymphoid 
hyperplasia, one cholangioadenoma, and one hemangioma, 
respectively.
The sensitivity, specificity, positive predictive value, nega-
tive predictive value, positive likelihood ratio, negative likeli-
hood ratio, and disease prevalence of WFUMB-EFSUMB cri-
teria for the diagnosis of HCCs were 88.6% (95% CI: 80.9%, 
94%), 87.1% (95% CI: 77%, 94%), 91.2% (95% CI: 84.8%, 
95%), 83.6% (95% CI: 74.8%, 89.7%), 6.9 (95% CI: 3.7, 
12.7), 0.1 (95% CI: 0.1, 0.2), and 60%, respectively (Table 
5). There were differences in sensitivity and specificity between 
CEUS LR-5 and WFUMB-EFSUMB criteria (P , .001 and 
P = .02, respectively).
CEUS LI-RADS Category and HCC Grading
In 104 pathologic analysis–proven HCCs, there was one well-
differentiated tumor, 78 moderately differentiated tumors, and 
25 poorly differentiated tumors.
Table 5: Diagnostic Performance of CEUS LI-RADS and WFUMB-EFSUMB Criteria
Criteria Sensitivity (%) Specificity (%) Accuracy (%)
CEUS LR-5 73.3 (77/105) [63.8, 81.5] 97.1 (68/70) [90.1, 99.7] 82.9 (145/175) [76.4, 88.1]
WFUMB-EFSUMB 88.6 (93/105) [80.9, 94] 87.1 (61/70) [77, 94] 88 (154/175) [82.2, 92.4]
P value of CEUS LR-5 vs WFUMB-EFSUMB ,.001 .02 .09
Note.—Data in parentheses are numerator/denominator and data in brackets are 95% confidence intervals. CEUS LI-RADS = contrast-
enhanced US Liver Imaging Reporting and Data System, EFSUMB = European Federation of Societies for Ultrasound in Medicine and 
Biology, WFUMB = World Federation for Ultrasound in Medicine and Biology.
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Figure 4: LR-4 nodule in a 60-year-old man with chronic hepatitis B. (a) A 2-cm hyperechoic nodule (arrow) was shown in the right lobe of the liver at conventional 
gray-scale US. (b) Homogeneous hyperenhancement (arrow) in the arterial phase was shown at contrast-enhanced US. (c) The enhancement persisted in the late phase 
without definite washout. (d) The lesion was assigned to LR-4 and dysplastic nodule was confirmed at histopathologic analysis; hematoxylin-eosin staining (magnification, 
3400).
Correlation between CEUS LI-RADS classification and 
HCC differentiation is in Table 6. Among the 15 HCCs classi-
fied as CEUS LR-M, six (40%) were poorly differentiated HCC. 
The rate of poorly differentiated HCCs classified as CEUS LR-5 
was only 23% (18 of 77). However, there was no difference in 
the rates of poorly differentiated HCCs between CEUS LR-M 
and CEUS LR-5 (P . .05).
Discussion
American College of Radiology contrast-enhanced US Liver Im-
aging Reporting and Data System (CEUS LI-RADS) was de-
veloped as a standardized reporting system for liver nodules in 
patients at risk for hepatocellular carcinoma (HCC) (14,16,19). 
However, the efficacy of CEUS LI-RADS in the diagnosis of 
HCC has not been widely validated, especially in small liver 
nodules. Only liver nodules 20 mm or smaller were included in 
this study, of which 105 of 175 nodules (60.0%) were HCCs. 
Compared with World Federation for Ultrasound in Medicine 
and Biology (WFUMB)2European Federation of Societies for 
Ultrasound in Medicine and Biology (EFSUMB) criteria, LR-5 
demonstrated higher specificity for diagnosing small HCC in pa-
tients at risk for HCC with lower sensitivity (97.1% vs 87.1% [P 
= .02] and 73.3% vs 88.6% [P , .001], respectively). In CEUS 
LI-RADS, CEUS LR-5 aims for high specificity and positive 
predictive value close to 100% in diagnosing HCC in patients 
at risk for HCCs. The positive predictive value of LR-5 reported 
by Terzi et al (20) was 98.5% with an HCC prevalence rate of 
81.5% (820 of 1006), similar to our study results. Two dysplastic 
nodules in our study were classified as LR-5 compared with three 
high-grade dysplastic nodules in Terzi et al. The development of 
HCC is thought to occur through a multistep pathway (21–23). 
Moreover, high-grade dysplastic nodule was regarded as an HCC 
precursor with a reported rate of HCC transformation close to 
99% (20). The hemodynamics of the contrast agent may over-
lap between high-grade dysplastic nodule and well-differentiated 
HCC (24,25). Therefore, dysplastic nodule may manifest with 
a similar enhancing pattern as that in well-differentiated small 
HCC.
CEUS LR-4 was designed to classify those lesions that are 
probably but not definitely HCC. Terzi et al reported a rate of 
Huang et al
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Figure 5: LR-M nodule in a 60-year-old woman with chronic hepatitis B. (a) A 1.9-cm hypoechoic nodule (arrow) was shown in segment VII at gray-scale US. (b) 
Homogeneous hyperenhancement of the nodule (arrow) in the arterial phase was shown at contrast-enhanced US. (c) Early washout of the contrast agent (,60 seconds) 
was observed (arrow) in the portal phase. (d) Mild washout of the nodule (arrow) in the late phase was observed. This lesion was assigned to LR-M according to its 
contrast-enhanced US findings. Poorly differentiated hepatocellular carcinoma and cirrhosis (stage 4) of surrounding liver were confirmed at histopathologic analysis.
HCC of 85.6% in LR-4 (20). However, we reported a relatively 
low HCC rate (11 of 23; 48%) in LR-4, possibly because of dif-
ferences in the examined study sample (European vs Asian eth-
nicity) and/or underlying liver disease (over 90% chronic hepati-
tis B in our study sample). The limited number of LR-4 nodules 
and higher rate of regenerative or dysplastic nodules (eight of 23; 
35%) may also contribute to this discrepancy.
Among 105 HCCs, washout onset within 60 seconds was 
observed in 14 nodules (13.3%). Those nodules were therefore 
classified as LR-M. Moreover, six of these nodules (42.9%) were 
poorly differentiated tumors. Early washout (,60 seconds) has 
been reported (5,26,27) to occur in poorly differentiated HCCs 
or to suggest a nonhepatocellular malignancy, which is in con-
cordance with our findings. Interestingly, although the rate of 
poorly differentiated HCCs in LR-M is nearly twofold to that 
in LR-5 (18 of 77; 23%), no significant difference between the 
rates was found, which is likely because of the small sample size 
of our study.
Two pathologic analysis–proven intrahepatic cholangiocar-
cinomas were included in our study sample and were classified 
as LR-M with nonrim arterial phase hyperenhancement, with 
marked washout in one nodule and early marked washout in 
the other nodule. Both nodules were regarded as HCC by 
WFUMB-EFSUMB criteria. Vilana et al (28) concluded that 
contrast-enhanced US could not help to differentiate HCC 
from intrahepatic cholangiocarcinoma. However, their diag-
nostic criteria did not include timing of washout onset time 
or washout intensity. Because the LR-M classification indicates 
malignancy not specific for HCC that requires tissue sampling, 
if intrahepatic cholangiocarcinoma can be accurately catego-
rized as LR-M, then CEUS LI-RADS has considerable diag-
nostic value.
There were several limitations to our study. First, because the 
topic was focused on small liver nodules, our study sample was 
relatively small, especially in the subgroup of LR-2, which was 
partly because patients with nodules smaller than 1 cm seldom 
underwent contrast-enhanced US in daily clinical practice. Sec-
ond, pathologic results were not available for all the nodules, 
especially for the LR-1, LR-2, and LR-3 subgroups, which could 
make more nodules eligible for inclusion but also compromise 
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Figure 6: LR-M nodule in a 46-year-old woman with chronic hepatitis B. (a) A 1.7-cm hypoechoic nodule (arrow) in the right liver lobe was shown at conventional 
gray-scale US. (b) The lesion was homogeneously hyperenhanced (arrow) in the arterial phase at contrast-enhanced US. (c) Early washout of the contrast agent (washout 
onset time, 49 seconds) was observed (arrow). (d) Marked washout (arrow) in the late phase was shown at contrast-enhanced US. The lesion was assigned to LR-M. 
Intrahepatic cholangiocarcinoma and septal fibrosis (stage 2) of the surrounding liver were confirmed at histopathologic analysis.
the reference standard strength. Third, no prospective validation 
of the findings was performed. Finally, our study sample was 
mainly composed of patients with chronic hepatitis B. There-
fore, our results may not be reproducible in patients with other 
etiologic causes.
A multicenter prospective study with a larger study sample 
is needed to validate the findings, such as the hypothesis that 
poorly differentiated HCC is more likely to be categorized 
as LR-M. A useful area of CEUS LI-RADS application is ra-
diomics. CEUS LI-RADS creates easily extractable imaging 
parameters (radiomic data) for contrast-enhanced US examina-
tions, thus providing help for future diagnostic explorations by 
simplifying extraction of imaging features, automation of image 
analysis, and improving mining of data to develop a model to 
predict clinical outcomes and improve management of the pa-
tients with indeterminate liver nodules.
Table 6: Correlation between CEUS LI-RADS Classification and Hepatocellular Carcinoma Differentiation
CEUS LI-RADS Classification Well-differentiated HCC Moderately Differentiated HCC Poorly Differentiated HCC
LR-3 NA 1 (1) NA
LR-4 NA 10 (13) 1 (4)
LR-5 1 (100) 58 (74) 18 (72)
LR-M NA 9 (12) 6 (24)
Total 1 78 25
Note.—Data are numbers of nodules; data in parentheses are percentages. CEUS LI-RADS = contrast-enhanced US Liver Imaging Report-
ing and Data System, HCC = hepatocellular carcinoma, NA = not available.
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In conclusion, American College of Radiology contrast-
enhanced US Liver Imaging Reporting and Data System clas-
sification of small liver nodules is reproducible in well-trained 
hands. Compared with World Federation for Ultrasound in 
Medicine and Biology2European Federation of Societies for 
Ultrasound in Medicine and Biology criteria, CEUS LR-5 
demonstrated higher specificity for diagnosing hepatocellu-
lar carcinomas (HCCs). LR-4 and LR-M classifications are 
highly suspicious for malignancy, but not specific enough for 
HCC, and therefore tissue sampling is recommended in this 
group. Our study also confirmed that LR-3 was more likely 
to be benign. Meanwhile, no lesion in LR-1 and LR-2 was 
malignant.
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